Form 4: Madrigal Pharmaceuticals Director Jacqualyn Fouse Receives Equity Grants

Madrigal Pharmaceuticals, Inc. Director Jacqualyn A. Fouse was granted 203 restricted stock units and options to purchase 366 shares of common stock, aligning her interests with shareholders.

Summary

• Jacqualyn A. Fouse, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported new equity grants.
• On June 20, 2025, Ms. Fouse was granted 203 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per share.
• These RSUs are set to vest on the date of the Issuer's annual meeting of stockholders in 2026, contingent on her continued service.
• Additionally, on June 20, 2025, Ms. Fouse was granted stock options to acquire 366 shares of common stock at an exercise price of $285.73 per share, with a transaction price of $0.
• These stock options will vest 100% on the date of the Issuer's annual meeting of stockholders in 2026, provided she continues to serve as a director.
• The stock options have an expiration date of June 20, 2035.
• Following these transactions, Ms. Fouse beneficially owns 1,097 shares of common stock and 366 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates standard director compensation and aligns insider interests with shareholders, without any negative implications.

Positives

• The equity grants align the interests of Director Jacqualyn A. Fouse with those of the company's shareholders, as her compensation is tied to future company performance and continued service.
• The grants are a standard form of compensation for directors, indicating ongoing commitment and retention of key board members.

Future Outlook

The restricted stock units and stock options granted to Director Jacqualyn A. Fouse are forward-looking, with vesting contingent upon her continued service with Madrigal Pharmaceuticals until the company's annual meeting of stockholders in 2026.

Industry Context

This filing represents a routine equity compensation grant to a director, a common practice across various industries, including pharmaceuticals, to incentivize long-term commitment and align leadership interests with company performance.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The restricted stock units and stock options are expected to vest on the date of Madrigal Pharmaceuticals' annual meeting of stockholders in 2026, provided the director continues in service.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, SEC Form 4, Director Compensation, Equity Grant, Restricted Stock Units, Stock Options, Insider Transaction, Corporate Governance